Showing results (241-250 of 266) with videos related to

Sort By:
Pageof 27
Iscience|December 24, 2025
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancerDaniel Westaby, Juan M Jiménez-Vacas, Ines Figueiredo, et al.
Cell Reports|September 27, 2025
IGF2BP3 redirects glycolytic flux to promote one-carbon metabolism and RNA methylationGunjan Sharma, Martin Gutierrez, Anthony E Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2018
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)Jonathan Welti, Adam Sharp, Wei Yuan, et al.
Bioorganic & Medicinal Chemistry Letters|May 27, 2008
Development of potent and selective small-molecule human Urotensin-II antagonistsJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
European Urology|June 9, 2021
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNASemini Sumanasuriya, George Seed, Harry Parr, et al.
Journal of Medicinal Chemistry|August 16, 2012
Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT)Hongfeng Deng, Heather O'Keefe, Christopher P Davie, et al.
The Journal of Clinical Investigation|June 4, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancerJuliet Carmichael, Ines Figueiredo, Bora Gurel, et al.
Nature Communications|May 28, 2025
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stressAndreas Varkaris, Keshan Wang, Mannan Nouri, et al.
Bioorganic & Medicinal Chemistry Letters|June 6, 2008
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profilesJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
Pageof 27